Skip to main content

Table 3 mutated genes in tumor samples #1, 3, 4, 5

From: Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

sample number number of (shared) affected genes by mutation affected genes
1,3,4,5 2 MYD88a, PIM1
1,4,5 2 BCL2a, ETV6
3,4,5 1 KMT2D
1,3 2 LPHN3, PRDM1
1,4 2 CD79Ba, SOCS1
1,5 2 IRF4, MYCa
4,5 3 FOXB1, LRP1Bc, HLA-B
1 13 LTF, EPHA5, EP400, SYNE1, BLNK, STAT3a, FES, SEPT9, POLR3A, DPYD, TFE3b, CSMD3, FAT1
3 14 KITa, MAGI1, TP53a, ASXL1a, SETD2a, IDH2a, MTRR, PBRM1, BCR, MN1, RNF213, TOP1a, ATMa, FANCMa
4 14 CDKN1Ba, PAX5, FOXO1, MCL1a, PTPRT, CARD11c, PPM1D, DST, BCL10, TCL1A, FN1, HSP90AA1a, NIN, SLCO1B1
5 17 HSP90AB1a, ARID5Ba, ETS1, ERBB4a, CCND2a, HLA-C, ITGB2, EPHA3, BCL6, TBL1XR1, PCBP1, RECQL4, CREBBP, STAT4a, MLLT3, KEAP1, BTKc
  1. aspecific mutations/CNVs/increased expression of these genes qualify for targetable therapies (incl. Preclinical compounds)
  2. bMutations in these genes may alter pharmacokinetics of drugs (Pharmacogenomics)
  3. cMutations in these genes are prohibitive for certain targetable therapies [53]